氨柔比星

**氨柔比星**
臨床資料
AHFS/Drugs.com	國際藥品名稱
給藥途徑	IV
ATC碼	L01DB10 (WHO) ;
法律規範狀態
法律規範	處方藥（℞-only）;
識別資訊
	IUPAC命名法 (7S,9S)-9-Acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; ;
CAS號	110267-81-7
PubChem CID	178149;
ChemSpider	2299344 ;
UNII	93N13LB4Z2;
KEGG	D08854 ;
ChEBI	CHEBI:135779;
ChEMBL	ChEMBL1186894 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID30869526 ;
化學資訊
化學式	C25H25NO9
摩爾質量	483.47 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@](C(=O)C)(N)C[C@@H]5O[C@@H]4OC[C@@H](O)[C@@H](O)C4;
	InChI InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1 ; Key:VJZITPJGSQKZMX-XDPRQOKASA-N ;

氨柔比星（INN：amrubicin；開發代號：SM-5887）是一種用於治療肺癌的蒽環類藥物。^[1]它自2002年起由住友製藥以商品名Calsed在日本銷售。^[2]

氨柔比星通過抑制拓撲異構酶II發揮作用，並在臨床試驗中與拓撲替康（拓撲異構酶I抑制劑）進行了比較。^[3]^[4]

它還被研究用於治療膀胱癌^[5]和胃癌。^[6]

氨柔比星是第一個通過從頭合成的蒽環類衍生物，由住友化學家的科學家於1989年首次發表。^[7]

參考資料

^ Ueoka H, Ohnoshi T, Kimura I. [New anthracycline analogues in the treatment of lung cancer]. Gan to Kagaku Ryoho. November 1992, 19 (13): 2146–9. PMID 1332624 （日語）.
^ Sumitomo Pharmaceuticals Co., Ltd. CALSED for Injection (English) (PDF). 2003 [2008-08-17]. ^{[失效連結]}
^ Celgene Corporation. Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer. 2008 [2009-07-10]. （原始內容存檔於2013-01-19）.
^ Medical News Today. Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer. 2007 [2009-07-10].
^ Ohmori H, Tsushima T, Kobashi K. [Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]. Gan to Kagaku Ryoho. April 1996, 23 (5): 601–6. PMID 8678519 （日語）.
^ Tsushima K, Sakata Y, Munakata A, et al. [A phase II study of SM-5887 for advanced gastric cancer]. Gan to Kagaku Ryoho. June 1991, 18 (7): 1151–4. PMID 1647150 （日語）.
^ Hanada M. Amrubicin, Chapter 6 in Case Studies in Modern Drug Discovery and Development. Eds. Huang X and Aslanian RG. John Wiley & Sons, 2012 ISBN 9780470601815 P 106